215 results on '"PLACENTA diseases"'
Search Results
2. SARS-CoV-2 placentitis, stillbirth, and maternal COVID-19 vaccination: clinical-pathologic correlations.
- Author
-
Schwartz, David A., Mulkey, Sarah B., and Roberts, Drucilla J.
- Subjects
COVID-19 vaccines ,STILLBIRTH ,SARS-CoV-2 ,PERINATAL death ,NEONATAL death ,TROPHOBLASTIC tumors ,PLACENTA diseases - Abstract
Stillbirth is a recognized complication of COVID-19 in pregnant women that has recently been demonstrated to be caused by SARS-CoV-2 infection of the placenta. Multiple global studies have found that the placental pathology present in cases of stillbirth consists of a combination of concurrent destructive findings that include increased fibrin deposition that typically reaches the level of massive perivillous fibrin deposition, chronic histiocytic intervillositis, and trophoblast necrosis. These 3 pathologic lesions, collectively termed SARS-CoV-2 placentitis, can cause severe and diffuse placental parenchymal destruction that can affect >75% of the placenta, effectively rendering it incapable of performing its function of oxygenating the fetus and leading to stillbirth and neonatal death via malperfusion and placental insufficiency. Placental infection and destruction can occur in the absence of demonstrable fetal infection. Development of SARS-CoV-2 placentitis is a complex process that may have both an infectious and immunologic basis. An important observation is that in all reported cases of SARS-CoV-2 placentitis causing stillbirth and neonatal death, the mothers were unvaccinated. SARS-CoV-2 placentitis is likely the result of an episode of SARS-CoV-2 viremia at some time during the pregnancy. This article discusses clinical and pathologic aspects of the relationship between maternal COVID-19 vaccination, SARS-CoV-2 placentitis, and perinatal death. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Placental pathology is necessary to understand common pregnancy complications and achieve an improved taxonomy of obstetrical disease.
- Author
-
Redline, Raymond W., Roberts, Drucilla J., Parast, Mana M., Ernst, Linda M., Morgan, Terry K., Greene, Michael F., Gyamfi-Bannerman, Cynthia, Louis, Judette M., Maltepe, Emin, Mestan, Karen K., Romero, Roberto, and Stone, Joanne
- Subjects
PLACENTA diseases ,PREGNANCY complications ,PLACENTA ,PREGNANCY outcomes ,PATHOLOGY ,RECURRENT miscarriage - Abstract
The importance of a fully functioning placenta for a good pregnancy outcome is unquestioned. Loss of function can lead to pregnancy complications and is often detected by a thorough placental pathologic examination. Placental pathology has advanced the science and practice of obstetrics and neonatal-perinatal medicine by classifying diseases according to underlying biology and specific patterns of injury. Many past obstacles have limited the incorporation of placental findings into both clinical studies and day-to-day practice. Limitations have included variability in the nomenclature used to describe placental lesions, a shortage of perinatal pathologists fully competent to analyze placental specimens, and a troubling lack of understanding of placental diagnoses by clinicians. However, the potential use of placental pathology for phenotypic classification, improved understanding of the biology of adverse pregnancy outcomes, the development of treatment and prevention, and patient counseling has never been greater. This review, written partly in response to a recent critique published in a major obstetrics-gynecology journal, reexamines the role of placental pathology by reviewing current concepts of biology; explaining the most recent terminology; emphasizing the usefulness of specific diagnoses for obstetrician-gynecologists, neonatologists, and patients; previewing upcoming changes in recommendations for placental submission; and suggesting future improvements. These improvements should include further consideration of overall healthcare costs, cost-effectiveness, the clinical value added of placental assessment, improvements in placental pathology education and practice, and leveraging of placental pathology to identify new biomarkers of disease and evaluate novel therapies tailored to specific clinicopathologic phenotypes of both women and infants. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. 211 Artificial intelligence-driven precision pathology identifies distinct placental findings in severe fetal growth restriction or hypertension.
- Author
-
Jacobs, Anna K., Al-Juboori, Saif I., Dobrinskikh, Evgenia, Bolt, Matthew A., Sammel, Mary, Lijewski, Virginia, Post, Miriam D., Small, James M., and Su, Emily
- Subjects
FETAL growth retardation ,PLACENTA ,PLACENTA diseases ,PATHOLOGY ,HYPERTENSION - Published
- 2024
- Full Text
- View/download PDF
5. Placental energy metabolism in health and disease-significance of development and implications for preeclampsia.
- Author
-
Aye, Irving L.M.H., Aiken, Catherine E., Charnock-Jones, D. Stephen, and Smith, Gordon C.S.
- Subjects
ENERGY metabolism ,PREECLAMPSIA ,PLACENTA ,GENE expression profiling ,METABOLIC disorders ,PLACENTA diseases ,HELLP syndrome - Abstract
The placenta is a highly metabolically active organ fulfilling the bioenergetic and biosynthetic needs to support its own rapid growth and that of the fetus. Placental metabolic dysfunction is a common occurrence in preeclampsia although its causal relationship to the pathophysiology is unclear. At the outset, this may simply be seen as an "engine out of fuel." However, placental metabolism plays a vital role beyond energy production and is linked to physiological and developmental processes. In this review, we discuss the metabolic basis for placental dysfunction and propose that the alterations in energy metabolism may explain many of the placental phenotypes of preeclampsia such as reduced placental and fetal growth, redox imbalance, oxidative stress, altered epigenetic and gene expression profiles, and the functional consequences of these aberrations. We propose that placental metabolic reprogramming reflects the dynamic physiological state allowing the tissue to adapt to developmental changes and respond to preeclampsia stress, whereas the inability to reprogram placental metabolism may result in severe preeclampsia phenotypes. Finally, we discuss common tested and novel therapeutic strategies for treating placental dysfunction in preeclampsia and their impact on placental energy metabolism as possible explanations into their potential benefits or harm. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. An integrated model of preeclampsia: a multifaceted syndrome of the maternal cardiovascular-placental-fetal array.
- Author
-
Yagel, Simcha, Cohen, Sarah M., and Goldman-Wohl, Debra
- Subjects
VASCULAR endothelial growth factor receptors ,HELLP syndrome ,MOLAR pregnancy ,ECTOPIC pregnancy ,PREECLAMPSIA ,PLACENTA diseases ,VASCULAR resistance - Abstract
Maternal tolerance of the semiallogenic fetus necessitates conciliation of competing interests. Viviparity evolved with a placenta to mediate the needs of the fetus and maternal adaptation to the demands of pregnancy and to ensure optimal survival for both entities. The maternal-fetal interface is imagined as a 2-dimensional porous barrier between the mother and fetus, when in fact it is an intricate multidimensional array of tissues and resident and circulating factors at play, encompassing the developing fetus, the growing placenta, the changing decidua, and the dynamic maternal cardiovascular system. Pregnancy triggers dramatic changes to maternal hemodynamics to meet the growing demands of the developing fetus. Nearly a century of extensive research into the development and function of the placenta has revealed the role of placental dysfunction in the great obstetrical syndromes, among them preeclampsia. Recently, a debate has arisen questioning the primacy of the placenta in the etiology of preeclampsia, asserting that the maternal cardiovascular system is the instigator of the disorder. It was the clinical observation of the high rate of preeclampsia in hydatidiform mole that initiated the focus on the placenta in the etiology of the disease. Over many years of research, shallow trophoblast invasion with deficient remodeling of the maternal spiral arteries into vessels of higher capacitance and lower resistance has been recognized as hallmarks of the preeclamptic milieu. The lack of the normal decrease in uterine artery resistance is likewise predictive of preeclampsia. In abdominal pregnancies, however, an extrauterine pregnancy develops without remodeling of the spiral arteries, yet there is reduced resistance in the uterine arteries and distant vessels, such as the maternal ophthalmic arteries. Proponents of the maternal cardiovascular model of preeclampsia point to the observed maternal hemodynamic adaptations to pregnancy and maladaptation in gestational hypertension and preeclampsia and how the latter resembles the changes associated with cardiac disease states. Recognition of the importance of the angiogenic-antiangiogenic balance between placental-derived growth factor and its receptor soluble fms-like tyrosine kinase-1 and disturbance in this balance by an excess of a circulating isoform, soluble fms-like tyrosine kinase-1, which competes for and disrupts the proangiogenic receptor binding of the vascular endothelial growth factor and placental-derived growth factor, opened new avenues of research into the pathways to normal adaptation of the maternal cardiovascular and other systems to pregnancy and maladaptation in preeclampsia. The significance of the "placenta vs heart" debate goes beyond the academic: understanding the mutuality of placental and maternal cardiac etiologies of preeclampsia has far-reaching clinical implications for designing prevention strategies, such as aspirin therapy, prediction and surveillance through maternal hemodynamic studies or serum placental-derived growth factor and soluble fms-like tyrosine kinase-1 testing, and possible treatments to attenuate the effects of insipient preeclampsia on women and their fetuses, such as RNAi therapy to counteract excess soluble fms-like tyrosine kinase-1 produced by the placenta. In this review, we will present an integrated model of the maternal-placental-fetal array that delineates the commensality among the constituent parts, showing how a disruption in any component or nexus may lead to the multifaceted syndrome of preeclampsia. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. 628 Association of disease severity and placental pathology changes in pregnant patients with SARS-CoV-2.
- Author
-
Wang, Juliann, Blanchard, Christina T., Seasely, Angela R., Duncan, Virginia E., Odom, Jodie Dionne, Subramaniam, Akila, and Arora, Nitin
- Subjects
SARS-CoV-2 ,PLACENTA ,PATHOLOGY ,PATIENTS ,PLACENTA diseases - Published
- 2024
- Full Text
- View/download PDF
8. Redefining maternal vascular malperfusion (MVM) placental disease by circulating placental growth factor (PlGF) level.
- Author
-
Zur, Rebecca L., McLaughlin, Kelsey, Aalto, Laura, Parks, W. Tony, and Kingdom, John C.
- Subjects
PLACENTAL growth factor ,PLACENTA ,PLACENTA diseases - Published
- 2023
- Full Text
- View/download PDF
9. SMFM Special Statement: State of the science on multifetal gestations: unique considerations and importance.
- Author
-
Grantz, Katherine L., Kawakita, Tetsuya, Lu, Ya-Ling, Newman, Roger, Berghella, Vincenzo, Caughey, Aaron, and SMFM Research Committee
- Subjects
PRENATAL care ,MULTIPLE pregnancy ,PREGNANCY ,PREGNANCY complications ,PLACENTA diseases ,MEDICAL research ,CLINICAL trials ,DISEASE susceptibility ,EXPERIMENTAL design ,PREMATURE infants ,MEDICAL societies ,RESEARCH funding ,SYMPTOMS ,FETAL development - Abstract
We sought to review the state of the science for research on multiple gestations. A literature search was performed with the use of PubMed for studies to quantify the representation of multiple gestations for a sample period (2012-2016) that were limited to phase III and IV randomized controlled trials, that were written in English, and that addressed at least 1 of 4 major pregnancy complications: fetal growth restriction or small-for-gestational-age fetus, gestational diabetes mellitus, preeclampsia, and preterm delivery. Of the 226 studies that are included in the analysis, multiple pregnancies were most represented in studies of preterm delivery: 17% of trials recruited both singleton and multiple pregnancies; another 18% of trials recruited only multiple pregnancies. For trials that studied preeclampsia, fetal growth restriction, and gestational diabetes mellitus, 17%, 8%, and 2%, respectively, recruited both singleton and multiple gestations. None of the trials on these 3 topics were limited to women with a multiple pregnancy. Women with a multiple pregnancy are at risk for complications similar to those of women with singleton pregnancies, but their risk is usually higher. Also, the pathophysiologic condition for some complications differs in multiple gestations from those that occur in singleton gestations. Conditions that are unique to multiple pregnancies include excess placenta, placental crowding or inability of the uteroplacental unit to support the normal growth of multiple fetuses, or suboptimal placental implantation sites with an increased risk of abnormal placental location. Other adverse outcomes in multiple gestations are also influenced by twin-specific risk factors, most notably chorionicity. Although twins have been well represented in many studies of preterm birth, these studies have failed to identify adequate predictive tests (short cervical length established over 2 decades ago remains the single best predictor), to establish effective interventions, and to differentiate the underlying pathophysiologic condition of twin preterm birth. Questions about fetal growth also remain. Twin growth deviates from that of singleton gestations starting at approximately 32 weeks of gestation; however, research with long-term follow-up is needed to better distinguish pathologic and physiologic growth deviations, which include growth discordance among pairs (or more). There are virtually no clinical trials that are specific to twins for gestational diabetes mellitus or preeclampsia, and subgroups for multiple pregnancies in existing trials are not large enough to allow definite conclusions. Another important area is the determination of appropriate maternal nutrition or micronutrient supplementation to optimize pregnancy and child health. There are also unique aspects to consider for research design in multiple gestations, such as designation and tracking of the correct fetus prenatally and through delivery. The correct statistical methods must be used to account for correlated data because multiple fetuses share the same mother and intrauterine environment. In summary, multiple gestations often are excluded from research studies, despite a disproportionate contribution to national rates of perinatal morbidity, mortality, and health-care costs. It is important to consider the enrollment of multifetal pregnancies in studies that target mainly women with singleton gestations, even when sample size is inadequate, so that insights that are specific to multiple gestations can be obtained when results of smaller studies are pooled together. The care of pregnant women with multiple gestations presents unique challenges; unfortunately, evidence-based clinical management that includes the diagnosis and treatment of common obstetrics problems are not well-defined for this population. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging.
- Author
-
Jauniaux, Eric, Collins, Sally, and Burton, Graham J
- Subjects
BLADDER ,FETAL ultrasonic imaging ,LABOR complications (Obstetrics) ,MYOMETRIUM ,PLACENTA ,PLACENTA diseases ,PLACENTA praevia ,PREGNANCY ,VASCULAR remodeling - Abstract
Placenta accreta spectrum is a complex obstetric complication associated with high maternal morbidity. It is a relatively new disorder of placentation, and is the consequence of damage to the endometrium-myometrial interface of the uterine wall. When first described 80 years ago, it mainly occurred after manual removal of the placenta, uterine curettage, or endometritis. Superficial damage leads primarily to an abnormally adherent placenta, and is diagnosed as the complete or partial absence of the decidua on histology. Today, the main cause of placenta accreta spectrum is uterine surgery and, in particular, uterine scar secondary to cesarean delivery. In the absence of endometrial reepithelialization of the scar area the trophoblast and villous tissue can invade deeply within the myometrium, including its circulation, and reach the surrounding pelvic organs. The cellular changes in the trophoblast observed in placenta accreta spectrum are probably secondary to the unusual myometrial environment in which it develops, and not a primary defect of trophoblast biology leading to excessive invasion of the myometrium. Placenta accreta spectrum was separated by pathologists into 3 categories: placenta creta when the villi simply adhere to the myometrium, placenta increta when the villi invade the myometrium, and placenta percreta where the villi invade the full thickness of the myometrium. Several prenatal ultrasound signs of placenta accreta spectrum were reported over the last 35 years, principally the disappearance of the normal uteroplacental interface (clear zone), extreme thinning of the underlying myometrium, and vascular changes within the placenta (lacunae) and placental bed (hypervascularity). The pathophysiological basis of these signs is due to permanent damage of the uterine wall as far as the serosa, with placental tissue reaching the deep uterine circulation. Adherent and invasive placentation may coexist in the same placental bed and evolve with advancing gestation. This may explain why no single, or set combination of, ultrasound sign(s) was found to be specific for the depth of abnormal placentation, and accurate for the differential diagnosis between adherent and invasive placentation. Correlation of pathological and clinical findings with prenatal imaging is essential to improve screening, diagnosis, and management of placenta accreta spectrum, and standardized protocols need to be developed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Diminished antiviral innate immune gene expression in the placenta following a maternal SARS-CoV-2 infection.
- Author
-
Coler, Brahm, Wu, Tsung-Yen, Carlson, Lindsey, Burd, Nicole, Munson, Jeff, Dacanay, Matthew, Cervantes, Orlando, Esplin, Sean, Kapur, Raj P., Feltovich, Helen, and Adams Waldorf, Kristina M.
- Subjects
PLACENTA diseases ,CHORIONIC villi ,SARS-CoV-2 ,GENE expression ,COVID-19 ,PEARSON correlation (Statistics) - Abstract
COVID-19 is caused by the SARS-CoV-2 virus and is associated with critical illness requiring hospitalization, maternal mortality, stillbirth, and preterm birth. SARS-CoV-2 has been shown to induce placental pathology. However, substantial gaps exist in our understanding of the pathophysiology of COVID-19 disease in pregnancy and the long-term impact of SARS-CoV-2 on the placenta and fetus. To what extent a SARS-CoV-2 infection of the placenta alters the placental antiviral innate immune response is not well understood. A dysregulated innate immune response in the setting of maternal COVID-19 disease may increase the risk of inflammatory tissue injury or placental compromise and may contribute to deleterious pregnancy outcomes. We sought to determine the impact of a maternal SARS-CoV-2 infection on placental immune response by evaluating gene expression of a panel of 6 antiviral innate immune mediators that act as biomarkers of the antiviral and interferon cytokine response. Our hypothesis was that a SARS-CoV-2 infection during pregnancy would result in an up-regulated placental antiviral innate immune response. We performed a case–control study on placental tissues (chorionic villous tissues and chorioamniotic membrane) collected from pregnant patients with (N=140) and without (N=24) COVID-19 disease. We performed real-time quantitative polymerase chain reaction and immunohistochemistry, and the placental histopathology was evaluated. Clinical data were abstracted. Fisher exact test, Pearson correlations, and linear regression models were used to examine proportions and continuous data between patients with active (<10 days since diagnosis) vs recovered COVID-19 (>10 days since diagnosis) at the time of delivery. Secondary regression models adjusted for labor status as a covariate and evaluated potential correlation between placental innate immune gene expression and other variables. SARS-CoV-2 viral RNA was detected in placental tissues from 5 women with COVID-19 and from no controls (0/24, 0%). Only 1 of 5 cases with detectable SARS-CoV-2 viral RNA in placental tissues was confirmed to express SARS-CoV-2 nucleocapsid and spike proteins in syncytiotrophoblast cells. We detected a considerably lower gene expression of 5 critical innate immune mediators (IFNB , IFIT1 , MXA , IL6 , IL1B) in the chorionic villi and chorioamniotic membranes from women with active or recovered COVID-19 than controls, which remained significant after adjustment for labor status. There were minimal correlations between placental gene expression and other studied variables including gestational age at diagnosis, time interval between COVID-19 diagnosis and delivery, prepregnancy body mass index, COVID-19 disease severity, or placental pathology. A maternal SARS-CoV-2 infection was associated with an impaired placental innate immune response in chorionic villous tissues and chorioamniotic membranes that was not correlated with gestational age at COVID-19 diagnosis, time interval from COVID-19 diagnosis to delivery, maternal obesity, disease severity, or placental pathology. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. Placental vascular malperfusion lesions are associated with hypertension, growth restriction, and antepartum hemorrhage and ultimately with fetal and preterm neonatal death.
- Author
-
Kulkarni, Vardendra G., McClure, Elizabeth M., and Goldenberg, Robert L.
- Subjects
NEONATAL death ,PLACENTA ,HEMORRHAGE ,HYPERTENSION ,AORTIC dissection ,PLACENTA diseases ,FETAL growth retardation ,PERINATAL death - Published
- 2022
- Full Text
- View/download PDF
13. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis.
- Author
-
Jauniaux, Eric and Bhide, Amar
- Subjects
CESAREAN section ,PRENATAL diagnosis ,ULTRASONIC imaging ,PLACENTA physiology ,MEDICAL screening ,FETAL ultrasonic imaging ,HYSTERECTOMY ,LABOR complications (Obstetrics) ,LONGITUDINAL method ,EVALUATION of medical care ,MEDLINE ,META-analysis ,PLACENTA diseases ,PLACENTA praevia ,PREGNANCY ,SYSTEMATIC reviews ,RETROSPECTIVE studies ,FERRANS & Powers Quality of Life Index ,IMPACT of Event Scale - Abstract
Background: Women with a history of previous cesarean delivery, presenting with a placenta previa, have become the largest group with the highest risk for placenta previa accreta.Objective: The objective of the study was to evaluate the accuracy of ultrasound imaging in the prenatal diagnosis of placenta accreta and the impact of the depth of villous invasion on management in women presenting with placenta previa or low-lying placenta and with 1 or more prior cesarean deliveries.Study Design and Data Sources: We searched PubMed, Google Scholar, clinicalTrials.gov, and MEDLINE for studies published between 1982 and November 2016.Study Eligibility Criteria: Criteria for the study were cohort studies that provided data on previous mode of delivery, placenta previa, or low-lying placenta on prenatal ultrasound imaging and pregnancy outcome. The initial search identified 171 records, of which 5 retrospective and 9 prospective cohort studies were eligible for inclusion in the quantitative analysis.Study Appraisal and Synthesis Methods: The studies were scored on methodological quality using the Quality Assessment of Diagnostic Accuracy Studies tool.Results: The 14 cohort studies included 3889 pregnancies presenting with placenta previa or low-lying placenta and 1 or more prior cesarean deliveries screened for placenta accreta. There were 328 cases of placenta previa accreta (8.4%), of which 298 (90.9%) were diagnosed prenatally by ultrasound. The incidence of placenta previa accreta was 4.1% in women with 1 prior cesarean and 13.3% in women with ≥2 previous cesarean deliveries. The pooled performance of ultrasound for the antenatal detection of placenta previa accreta was higher in prospective than retrospective studies, with a diagnostic odds ratios of 228.5 (95% confidence interval, 67.2-776.9) and 80.8 (95% confidence interval, 13.0-501.4), respectively. Only 2 studies provided detailed data on the relationship between the depth of villous invasion and the number of previous cesarean deliveries, independently of the depth of the villous invasion. A cesarean hysterectomy was performed in 208 of 232 cases (89.7%) for which detailed data on management were available. Positive correlations were found in the largest prospective studies between the cumulative rates of the more invasive forms of accreta placentation and the sensitivity and specificity of ultrasound imaging but not with diagnostic odds ratio values. We found no data on the ultrasound screening of placenta accreta at the routine midtrimester ultrasound examination from the nonexpert ultrasound units.Conclusion: Planning individual management for delivery is possible only with accurate evaluation of prenatal risk of accreta placentation in women presenting with a low-lying placenta/previa and a history of prior cesarean delivery. Ultrasound is highly sensitive and specific in the prenatal diagnosis of accreta placentation when performed by skilled operators. Developing a prenatal screening protocol is now essential to further improve the outcome of this increasingly more common major obstetric complication. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
14. Placental delayed villous maturation is associated with fetal congenital heart disease.
- Author
-
O'Hare, Clare B., Mangin-Heimos, Kathryn S., Gu, Hongjie, Edmunds, Miranda, Bebbington, Michael, Lee, Caroline K., He, Mai, and Ortinau, Cynthia M.
- Subjects
PLACENTA diseases ,CONGENITAL heart disease ,FETAL heart ,INFANT physiology ,PLACENTA ,PREGNANCY complications - Abstract
The placenta is crucial for the overall development and lifelong health of the fetus. Abnormal placental development and function occur in pregnancies with fetal congenital heart disease. However, studies that use standardized diagnostic criteria and incorporate control populations are lacking. This limits the generalizability of current research and the ability to determine the specific placental abnormalities associated with congenital heart disease. This study applied consensus statement guidelines (known as the Amsterdam criteria) for placental pathology interpretation to compare the frequency and pattern of abnormalities in pregnancies with fetal congenital heart disease to demographically matched control pregnancies and evaluate for differences in placental abnormalities by cardiac physiology. A single-center retrospective cohort study was conducted from January 2013 to June 2019. Infants with a prenatal diagnosis of moderate-severe congenital heart disease who were born at ≥37 weeks of gestation were included. A control group born at ≥37 weeks of gestation but without fetal congenital heart disease or other major pregnancy complications was matched to the congenital heart disease group on maternal race and ethnicity and infant sex. Using the Amsterdam criteria, placental pathology findings were categorized as delayed villous maturation, maternal vascular malperfusion, fetal vascular malperfusion, and inflammatory lesions. The frequency of placental abnormalities was compared between groups, and logistic regression was performed to evaluate the association of clinical and sociodemographic factors with delayed villous maturation, maternal vascular malperfusion, and fetal vascular malperfusion. There were 194 pregnancies with fetal congenital heart disease and 105 controls included, of whom 83% in the congenital heart disease group and 82% in the control group were of non-Hispanic White race and ethnicity. Compared with controls, pregnancies with fetal congenital heart disease had higher rates of delayed villous maturation (6% vs 19%; P <.001) and maternal vascular malperfusion (19% vs 34%; P =.007) but not fetal vascular malperfusion (6% vs 10%; P=.23). Infants with congenital heart disease with 2-ventricle anatomy displayed the highest odds of delayed villous maturation compared with controls (odds ratio, 5.5; 95% confidence interval, 2.2–15.7; P <.01). Maternal vascular malperfusion was 2.2 times higher (P=.02) for infants with 2-ventricle anatomy and 2.9 times higher (P=.02) for infants with single-ventricle physiology with pulmonic obstruction. Within the congenital heart disease group, delayed villous maturation was associated with higher maternal body mass index, polyhydramnios, larger infant birth head circumference, and infant respiratory support in the delivery room, whereas maternal vascular malperfusion was associated with oligohydramnios. In multivariable models adjusting for cardiac diagnosis, associations of delayed villous maturation persisted for infant birth head circumference (odds ratio, 1.2; 95% confidence interval, 1.0–1.5; P=.02) and infant respiratory support in the delivery room (odds ratio, 3.0; 95% confidence interval, 1.3–6.5; P=.007). Pregnancies with fetal congenital heart disease displayed higher rates of delayed villous maturation and maternal vascular malperfusion than controls, suggesting that placental maldevelopment may relate to maternal factors. Future investigations are needed to determine the association of these abnormalities with postnatal infant outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
15. Accreta placentation: a systematic review of prenatal ultrasound imaging and grading of villous invasiveness.
- Author
-
Jauniaux, Eric, Collins, Sally L., Jurkovic, Davor, and Burton, Graham J.
- Subjects
PRENATAL diagnosis ,MYOMETRIUM ,DELIVERY (Obstetrics) ,DIAGNOSIS of placenta diseases ,STATISTICAL correlation ,FETAL ultrasonic imaging ,LABOR complications (Obstetrics) ,PLACENTA diseases ,SYSTEMATIC reviews ,THREE-dimensional imaging ,COLOR Doppler ultrasonography ,SEVERITY of illness index ,PHYSIOLOGY - Abstract
Background: Determining the depth of villous invasiveness before delivery is pivotal in planning individual management of placenta accreta. We have evaluated the value of various ultrasound signs proposed in the international literature for the prenatal diagnosis of accreta placentation and assessment of the depth of villous invasiveness.Objective: We undertook a PubMed and MEDLINE search of the relevant studies published from the first prenatal ultrasound description of placenta accreta in 1982 through March 30, 2016, using key words "placenta accreta," "placenta increta," "placenta percreta," "abnormally invasive placenta," "morbidly adherent placenta," and "placenta adhesive disorder" as related to "sonography," "ultrasound diagnosis," "prenatal diagnosis," "gray-scale imaging," "3-dimensional ultrasound", and "color Doppler imaging."Study Design: The primary eligibility criteria were articles that correlated prenatal ultrasound imaging with pregnancy outcome. A total of 84 studies, including 31 case reports describing 38 cases of placenta accreta and 53 series describing 1078 cases were analyzed. Placenta accreta was subdivided into placenta creta to describe superficially adherent placentation and placenta increta and placenta percreta to describe invasive placentation.Results: Of the 53 study series, 23 did not provide data on the depth of villous myometrial invasion on ultrasound imaging or at delivery. Detailed correlations between ultrasound findings and placenta accreta grading were found in 72 cases. A loss of clear zone (62.1%) and the presence of bridging vessels (71.4%) were the most common ultrasound signs in cases of placenta creta. In placenta increta, a loss of clear zone (84.6%) and subplacental hypervascularity (60%) were the most common ultrasound signs, whereas placental lacunae (82.4%) and subplacental hypervascularity (54.5%) were the most common ultrasound signs in placenta percreta. No ultrasound sign or a combination of ultrasound signs were specific of the depth of accreta placentation.Conclusion: The wide heterogeneity in terminology used to describe the grades of accreta placentation and differences in study design limits the evaluation of the accuracy of ultrasound imaging in the screening and diagnosis of placenta accreta. This review emphasizes the need for further prospective studies using a standardized evidence-based approach including a systematic correlation between ultrasound signs of placenta accreta and detailed clinical and pathologic examinations at delivery. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
16. A descriptive comparison of placental pathology in Covid-19 patients with and without hypertensive disease (HTND).
- Author
-
Nittur, Nandini R., Chithiwala, Zahabiya H., Mo, Lihong, and Tache, Veronique
- Subjects
COVID-19 ,HYPERTENSION ,PLACENTA ,PATHOLOGY ,PLACENTA diseases - Published
- 2022
- Full Text
- View/download PDF
17. Placental findings in SARS-CoV-2 maternal infection by severity and timing of maternal disease.
- Author
-
Gabby, Lauryn C., Jones, Chelsea, McIntyre, Brendan B., Ramos, Gladys A., Jacobs, Marni B., and Parast, Mana M.
- Subjects
SARS-CoV-2 ,PLACENTA ,INFECTION ,TIME ,PLACENTA diseases - Published
- 2022
- Full Text
- View/download PDF
18. Diagnostic utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction.
- Author
-
Agrawal, Swati, Parks, W. Tony, Zeng, Helen Dehui, Ravichandran, Anjana, Ashwal, Eran, Windrim, Rory C., Hobson, Sebastian R., Melamed, Nir, and Kingdom, John C.
- Subjects
PLACENTA diseases ,PLACENTAL growth factor ,HIGH-risk pregnancy ,UTERINE artery ,VASCULAR endothelial growth factors ,FETAL growth retardation - Abstract
Background: Placental pathology assessment following delivery in pregnancies complicated by preeclampsia, fetal growth restriction, abruption, and stillbirth reveals a range of underlying diseases. The most common pathology is maternal vascular malperfusion, characterized by high-resistance uterine artery Doppler waveforms and abnormal expression of circulating maternal angiogenic growth factors. Rare placental diseases (massive perivillous fibrinoid deposition and chronic histiocytic intervillositis) are reported to have high recurrence risks, but their associations with uterine artery Doppler waveforms and angiogenic growth factors are presently ill-defined.Objective: To characterize the patterns of serial placental growth factor measurements and uterine artery Doppler waveform assessments in pregnancies that develop specific types of placental pathology to gain insight into their relationships with the timing of disease onset and pregnancy outcomes.Study Design: A retrospective cohort study conducted between January 2017 and November 2021 included all singleton pregnancies with at least 1 measurement of maternal circulating placental growth factor between 16 and 36 weeks' gestation, delivery at our institution, and placental pathology analysis demonstrating diagnostic features of maternal vascular malperfusion, fetal vascular malperfusion, villitis of unknown etiology, chronic histiocytic intervillositis, or massive perivillous fibrinoid deposition. Profiles of circulating placental growth factor as gestational age advanced were compared between these placental pathologies. Maternal and perinatal outcomes were recorded.Results: A total of 337 pregnancies from 329 individuals met our inclusion criteria. These comprised placental pathology diagnoses of maternal vascular malperfusion (n=109), fetal vascular malperfusion (n=87), villitis of unknown etiology (n=96), chronic histiocytic intervillositis (n=16), and massive perivillous fibrinoid deposition (n=29). Among patients who developed maternal vascular malperfusion, placental growth factor levels gradually declined as pregnancy progressed (placental growth factor <10th percentile at 16-20 weeks' gestation in 42.9%; 20-24 weeks in 61.9%; 24-28 weeks in 77%; and 28-32 weeks in 81.4%) accompanied by mean uterine artery Doppler pulsatility index >95th percentile in 71.6% cases. Patients who developed either fetal vascular malperfusion or villitis of unknown etiology mostly exhibited normal circulating placental growth factor values in association with normal uterine artery Doppler waveforms (mean [standard deviation] pulsatility index values: fetal vascular malperfusion, 1.14 [0.49]; villitis of unknown etiology, 1.13 [0.45]). Patients who developed either chronic histiocytic intervillositis or massive perivillous fibrinoid deposition exhibited persistently low placental growth factor levels from the early second trimester (placental growth factor <10th centile at 16-20 weeks' gestation in 80% and 77.8%, respectively; 20-24 weeks in 88.9% and 63.6%; 24-28 weeks in 85.7% and 75%), all in combination with normal uterine artery Doppler waveforms (mean pulsatility index >95th centile: chronic histiocytic intervillositis, 25%; massive perivillous fibrinoid deposition, 37.9%). Preeclampsia developed in 83 of 337 (24.6%) patients and was most common in those developing maternal vascular malperfusion (54/109, 49.5%) followed by chronic histiocytic intervillositis (7/16, 43.8%). There were 29 stillbirths in the cohort (maternal vascular malperfusion, n=10 [9.2%]; fetal vascular malperfusion, n=5 [5.7%]; villitis of unknown etiology, n=1 [1.0%]; chronic histiocytic intervillositis, n=7 [43.8%]; massive perivillous fibrinoid deposition, n=6 [20.7%]). Most patients experiencing stillbirth exhibited normal uterine artery Doppler waveforms (21/29, 72.4%) and had nonmaternal vascular malperfusion pathologies (19/29, 65.5%). By contrast, 28 of 29 (96.5%) patients experiencing stillbirth had ≥1 low placental growth factor values before fetal death.Conclusion: Serial circulating maternal placental growth factor tests, in combination with uterine artery Doppler waveform assessments in the second trimester, may indicate the likely underlying type of placental pathology mediating severe adverse perinatal events. This approach has the potential to test disease-specific therapeutic strategies to improve clinical outcomes. Serial placental growth factor testing, compared with uterine artery Doppler studies, identifies a greater proportion of patients destined to have a poor perinatal outcome because diseases other than maternal vascular malperfusion are characterized by normal uteroplacental circulation. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
19. Placental vascular malperfusion lesions in fetal congenital heart disease.
- Author
-
Leon, Rachel L., Sharma, Kavita, Mir, Imran N., Herrera, Christina L., Brown, Steven L., Spong, Catherine Y., and Chalak, Lina F.
- Subjects
CONGENITAL heart disease ,FETAL heart ,PLACENTA diseases ,PLACENTA praevia ,SMALL for gestational age ,PLACENTA ,FETAL brain ,INFLAMMATION ,FETAL growth retardation ,RETROSPECTIVE studies ,FETUS ,QUESTIONNAIRES ,DISEASE complications - Abstract
Background: Fetuses with congenital heart disease are at increased risk of perinatal morbidity and mortality, which is highly influenced by their prenatal health. Placental function is vital for the health of the fetus, but increased rates of pathologic lesions of the placenta have been observed in pregnancies complicated by fetal congenital heart disease.Objective: This study aimed to determine the prevalence of both gross and histologic placental pathologies in a cohort of pregnancies complicated by fetal congenital heart disease vs healthy controls using the Amsterdam Placental Workshop Group Consensus Statement sampling and definitions of placental lesions.Study Design: This single-center retrospective cohort study included placental examinations from pregnancies diagnosed prenatally with fetal congenital heart disease between 2010 and 2019; moreover, control placentas were collected from pregnancies without maternal or fetal complications. Placentas were sampled and evaluated according to the Amsterdam Placental Workshop Group Consensus Statement and gross and histopathologic diagnoses determined.Results: Approximately 80% of fetuses diagnosed with congenital heart disease (n=305) had a placental examination for comparison with controls (n=40). Of note, 239 placentas (78%) in the group with fetal congenital heart disease had at least 1 gross or histopathologic lesion compared with 11 placentas (28%) in the control group (P<.01). One-third of placentas complicated by fetal congenital heart disease met the criteria for small for gestational age, and 48% of placentas had one or more chronic lesions, including maternal vascular malperfusion (23% vs 0%; P<.01), villitis of unknown etiology (22% vs 0%; P<.01), fetal vascular malperfusion (20% vs 0%; P<.01), and other chronic lesions (16% vs 0%; P<.01). Acute inflammation was equally present in both the group with fetal congenital heart disease and the control group (28% vs 28%; P=1.00). Although gestational age and birthweight z score were similar between the 2 groups, birth head circumference was 1.5 cm less in pregnancies complicated by fetal congenital heart disease with a significantly lower z score compared with the control group (-0.52±1.22 vs 0.06±0.69; P<.01).Conclusion: Vascular malperfusion lesions and chronic forms of inflammation occur at markedly higher rates in placentas complicated by fetal congenital heart disease, which may contribute to the decreased head circumference at birth. Further work in neuroplacentology is needed to explore connections among cardiac defects, placental vascular malperfusion lesions, and fetal brain development. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
20. Cerebral palsy: causes, pathways, and the role of genetic variants.
- Author
-
MacLennan, Alastair H., Thompson, Suzanna C., and Gecz, Jozef
- Subjects
CEREBRAL palsy ,ETIOLOGY of diseases ,CLINICAL trials ,CESAREAN section ,EPIDEMIOLOGY education ,HUMAN abnormalities ,DIAGNOSTIC errors ,FETAL growth retardation ,FETAL heart rate monitoring ,GENETICS ,PREMATURE infants ,INFECTION ,LABOR complications (Obstetrics) ,MALPRACTICE ,INBORN errors of metabolism ,MULTIPLE pregnancy ,GENETIC mutation ,PLACENTA diseases ,PREGNANCY complications ,SEX distribution ,CEREBRAL anoxia-ischemia ,DYSTOCIA ,DISEASE complications - Abstract
Cerebral palsy (CP) is heterogeneous with different clinical types, comorbidities, brain imaging patterns, causes, and now also heterogeneous underlying genetic variants. Few are solely due to severe hypoxia or ischemia at birth. This common myth has held back research in causation. The cost of litigation has devastating effects on maternity services with unnecessarily high cesarean delivery rates and subsequent maternal morbidity and mortality. CP rates have remained the same for 50 years despite a 6-fold increase in cesarean birth. Epidemiological studies have shown that the origins of most CP are prior to labor. Increased risk is associated with preterm delivery, congenital malformations, intrauterine infection, fetal growth restriction, multiple pregnancy, and placental abnormalities. Hypoxia at birth may be primary or secondary to preexisting pathology and international criteria help to separate the few cases of CP due to acute intrapartum hypoxia. Until recently, 1-2% of CP (mostly familial) had been linked to causative mutations. Recent genetic studies of sporadic CP cases using new-generation exome sequencing show that 14% of cases have likely causative single-gene mutations and up to 31% have clinically relevant copy number variations. The genetic variants are heterogeneous and require function investigations to prove causation. Whole genome sequencing, fine scale copy number variant investigations, and gene expression studies may extend the percentage of cases with a genetic pathway. Clinical risk factors could act as triggers for CP where there is genetic susceptibility. These new findings should refocus research about the causes of these complex and varied neurodevelopmental disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Conservative management of morbidly adherent placenta: expert review.
- Author
-
Fox, Karin A., Shamshirsaz, Alireza A., Carusi, Daniela, Secord, Angeles Alvarez, Lee, Paula, Turan, Ozhan M., Huls, Christopher, Abuhamad, Alfred, Simhan, Hyagriv, Barton, John, Wright, Jason, Silver, Robert, and Belfort, Michael A.
- Subjects
PLACENTA diseases ,CESAREAN section ,TREATMENT effectiveness ,CLINICAL trials ,PHYSICIANS ,ARTERIAL surgery ,ENZYME inhibitors ,HEMORRHAGE prevention ,METHOTREXATE ,MYOMETRIUM surgery ,PUERPERAL disorders ,PREVENTION of surgical complications ,LABOR complications (Obstetrics) ,SURGICAL blood loss ,CATHETERIZATION ,HYSTERECTOMY ,HYSTEROSCOPY ,LIGATURE (Surgery) ,MEDICAL care ,PATIENTS ,PRENATAL diagnosis ,THERAPEUTICS ,THERAPEUTIC embolization ,UTERINE artery ,PREVENTION - Abstract
Over the last century, the incidence of placenta accreta, increta, and percreta, collectively referred to as morbidly adherent placenta, has risen dramatically. Planned cesarean hysterectomy at the time of cesarean delivery is the standard recommended treatment in the United States. Recently, interest in conservative management has resurged, especially in Europe. The aims of this review are the following: (1) to provide an overview of methods used for conservative management, (2) to discuss clinical implications for both clinicians and patients, and (3) to identify areas in need of further research. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. The potential perinatal origin of placentation disorders in the young primigravida.
- Author
-
Brosens, Ivo, Benagiano, Giuseppe, and Brosens, Jan J.
- Subjects
PERINATAL care ,PLACENTA diseases ,FETAL development ,PROGESTERONE ,TROPHOBLAST ,PREECLAMPSIA ,PATIENTS - Abstract
The fetus is exposed to high plasma concentrations of unbound estrogens and progesterone throughout pregnancy. However, secretory or decidual changes in the fetal uterus occur relatively infrequently before birth, suggesting a variable endometrial progesterone response at the time of birth. Arguably, partial progesterone resistance that persists into adolescent years may compromise the physiological transformation of the spiral arteries and predispose for defective placentation in the case of pregnancy. Decidualization of the endometrial stromal compartment and junctional zone myometrium precedes trophoblast invasion. It represents the first step in the process of spiral artery remodeling needed to establish effective uteroplacental blood flow by midpregnancy. The major obstetric syndromes caused by impaired placental bed spiral artery remodeling are prevalent in teenage pregnancies, including preeclampsia, fetal growth restriction, and spontaneous preterm labor. Preconditioning of the uterus in response to cyclic menstruation during adolescence may be critical to achieve full uterine responsiveness to hormonal cues. Understanding the mechanisms of functional maturation of the uterus during the early reproductive years may yield novel insights into the major obstetric syndromes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
23. 1018 Microscopic focus of accreta on placental pathology: clinical context impacts morbidity risks in subsequent pregnancy.
- Author
-
Le, Gianna, Schauer, Galen, Weintraub, Miranda, Hung, Yun-Yi, and Greenberg, Mara
- Subjects
CLINICAL pathology ,PLACENTA diseases ,PREGNANCY ,CESAREAN section ,PREGNANCY outcomes ,DISEASES - Published
- 2021
- Full Text
- View/download PDF
24. 565 Timing of COVID-19 during pregnancy and impact on placental pathology.
- Author
-
Glynn, Shannon M., Yang, Yawei J., Thomas, Charlene, Friedlander, Rachel L., Cagino, Kristen, Matthews, Kathy, Riley, Laura E., Baergen, Rebecca, and Prabhu, Malavika
- Subjects
COVID-19 ,PLACENTA diseases ,PATHOLOGY ,PREGNANCY ,SARS-CoV-2 - Published
- 2021
- Full Text
- View/download PDF
25. 458 Maternal passive-smoking during pregnancy. the effect on pregnancy outcomes and placental-pathology. A prospective case-control study.
- Author
-
Levy, Michal, Kovo, Michal, Ben ezry, Emily, Torem, Maya, Shahaf, Hadar, Anchel, Noa, Bar, Jacob, Schreiber, Letizia, and Weiner, Eran
- Subjects
PREGNANCY outcomes ,PLACENTA diseases ,CASE-control method ,PREGNANCY ,LONGITUDINAL method ,AMNIOTIC liquid - Published
- 2021
- Full Text
- View/download PDF
26. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction.
- Author
-
McLaughlin, Kelsey, Hobson, Sebastian R., Chandran, Anjana Ravi, Agrawal, Swati, Windrim, Rory C., Parks, W. Tony, Bowman, Adrian W., Sovio, Ulla, Smith, Gordon C., and Kingdom, John C.
- Subjects
PLACENTAL growth factor ,LOW-molecular-weight heparin ,PLACENTA diseases ,CHORIONIC villi ,FETAL growth retardation ,PREGNANCY outcomes - Abstract
Background: Patients at high risk of severe preeclampsia and fetal growth restriction have low circulating levels of placental growth factor and features of maternal vascular malperfusion placental pathology at delivery. Multimodal screening and commencement of aspirin prophylaxis at 11 to 13 weeks' gestation markedly reduces the risk of preterm delivery with preeclampsia. However, the additional role of low-molecular-weight heparin and mechanisms of action remain uncertain. Because low-molecular-weight heparin augments the production and release of placental growth factor in vitro by both placental villi and vascular endothelium, it may be effective to suppress the risk of severe preeclampsia in a niche group of high-risk patients with low circulating placental growth factor in the early second trimester.Objective: This study aimed to define a gestational age-specific reference range for placental growth factor and to test the hypothesis that prophylactic low-molecular-weight heparin administered in the early second trimester may restore deficient circulating placental growth factor levels and thereby prolong pregnancy.Study Design: Centile curves for circulating placental growth factor levels from 12 to 36 weeks' gestation were derived using quantile regression of combined data from a published cohort of 4207 unselected nulliparous patients in Cambridge, United Kingdom, at 4 sampling time points (12, 20, 28, and 36 weeks' gestation) and the White majority (n=531) of a healthy nulliparous cohort in Toronto, Canada, at 16 weeks' gestation using the same test platform. Within a specialty high-risk clinic in Toronto, a niche group of 7 patients with a circulating placental growth factor at the <10th centile in the early second trimester received daily prophylactic low-molecular-weight heparin (enoxaparin; 40 mg subcutaneously) and were followed up until delivery (group 1). Their baseline characteristics, delivery details, and placental pathologies were compared with 5 similar patients who did not receive low-molecular-weight heparin during the observation period (group 2) and further with 21 patients who delivered with severe preeclampsia (group 3) in the same institution.Results: A gestational age-specific reference range for placental growth factor levels at weekly intervals between 12 and 36 weeks was established for White women with singleton pregnancies. Within group 1, 5 of 7 patients demonstrated a sustained increase in circulating placental growth factor levels, whereas placental growth factor levels did not increase in group 2 or group 3 patients who did not receive low-molecular-weight heparin. Group 1 patients receiving low-molecular-weight heparin therapy exhibited a later gestation at delivery, relative to groups 2 and 3 (36 weeks [33-37] vs 23 weeks [22-26] and 28 weeks [27-31], respectively), and consequently had higher birthweights (1.93 kg [1.1-2.7] vs 0.32 kg [0.19-0.39] and 0.73 kg [0.52-1.03], respectively). The incidence of stillbirth was lowest in group 1 (14% [1 of 7]), relative to groups 2 and 3 (80% [4 of 5] and 29% [6 of 21], respectively). Maternal vascular malperfusion was the most common placental pathology found in association with abnormal uterine artery Doppler.Conclusion: In patients at high risk of a serious adverse pregnancy outcome owing to placental disease, the addition of low-molecular-weight heparin to aspirin prophylaxis in the early second trimester may restore deficient circulating placental growth factor to mediate an improved perinatal outcome. These data support the implementation of a multicenter pilot randomized control trial where patients are recruited primarily based on the assessment of placental function in the early second trimester. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
27. Outcomes associated with antibiotic administration for isolated maternal fever in labor.
- Author
-
Bank, Tracy Caroline, Nuss, Emily, Subedi, Keshab, Hoffman, Matthew K., and Sciscione, Anthony
- Subjects
CHORIOAMNIONITIS ,PLACENTA diseases ,NEONATAL intensive care units ,ANTIBIOTICS ,STREPTOCOCCUS agalactiae ,PREMATURE labor ,ABRUPTIO placentae ,DATABASES ,FEVER ,ENDOMETRIAL diseases ,RETROSPECTIVE studies ,PREGNANCY outcomes ,PREGNANCY complications ,RESEARCH funding ,DELIVERY (Obstetrics) ,LABOR (Obstetrics) ,APGAR score - Abstract
Background: The American College of Obstetricians and Gynecologists currently recommends that antibiotic treatment should be considered for women with isolated maternal fevers during labor. However, there is little known about the maternal and neonatal impact of antibiotic treatment in this scenario.Objective: We sought to assess the outcomes in women with a nonsustained, isolated maternal fever treated with antibiotics and compare it with expectant management.Study Design: This was a retrospective cohort study of laboring women with a singleton gestation at term and a single temperature of between 38.0°C and 38.9°C without other evidence of infection (leukocytosis >15,000/mm3, fetal tachycardia, malodorous amniotic fluid, suspected alternate source of infection) at a tertiary teaching hospital. A contemporaneously maintained, validated obstetrical database was used to identify women for our cohort. Women with rheumatologic or renal disease, nongestational diabetes, preterm labor, placental abruption, vaginal bleeding, HIV, malpresentation, and fetal anomalies were excluded. The primary outcome was a postpartum fever above 38.0°C. Secondary maternal outcomes were treatment for postpartum endometritis, uterine atony, postpartum hemorrhage, admission to the intensive care unit, and postpartum length of stay. Secondary neonatal outcomes were neonatal intensive care unit admission, 5-minute Apgar score of <7, 5-minute Apgar score of <4, neonatal intensive care unit length of stay, and neonatal antibiotic administration. The results were compared using univariable and multivariable analyses.Results: From January 1, 2015, to December 31, 2018, 359 women were identified; 85 received antibiotics and 274 did not. The baseline characteristics were similar between the groups, except for gestational age at the time of delivery (39.2 weeks vs 39.5 weeks for the antibiotic and no antibiotic groups, respectively; P=.02). The incidence in postpartum fever showed a downward trend in the antibiotic group (10.59% for the antibiotic group vs 18.98% for the no antibiotic group; P=.07). Significantly fewer women in the antibiotic group were treated for postpartum endometritis (3.53% vs 11.31%; P=.03). Neonatal intensive care unit admission and neonatal antibiotic administration rates were higher in the antibiotic group (41.18% vs 17.88%; P<.001 and 36.47% vs 12.41%; P<.001, respectively). The incidence of 5-minute Apgar score of <7 was higher in the antibiotic group (8.25% vs 2.19%; P=.016). After controlling for age, gestational age, body mass index, group B streptococci status, delivery method, parity, administration of epidural, and receipt of acetaminophen, the odds for postpartum fever were reduced by a factor of 0.42 (95% confidence interval, 0.18-0.99) among women who received antibiotics when compared with those who did not receive antibiotics. Outcome results are presented in Table 2.Conclusion: Although there was a lower rate of treatment for endometritis among women who received antibiotics for a single isolated maternal fever, there was a higher rate of neonatal intensive care unit admissions and 5-minute Apgar score of <7. This indicates that there likely is maternal benefit associated with antibiotic use, however, there are concerns about the neonatal risk. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
28. Reply.
- Author
-
Jauniaux, Eric and Hussein, Ahmed M.
- Subjects
PRENATAL diagnosis ,LABOR complications (Obstetrics) ,PLACENTA diseases ,PLACENTA praevia - Published
- 2020
- Full Text
- View/download PDF
29. Unforeseen consequences of the increasing rate of cesarean deliveries: early placenta accreta and cesarean scar pregnancy. A review.
- Author
-
Timor-Tritsch, Ilan E. and Monteagudo, Ana
- Subjects
CESAREAN section ,DELIVERY (Obstetrics) ,PLACENTA diseases ,PREGNANCY complications ,SYSTEMATIC reviews ,METHOTREXATE ,LITERATURE reviews ,TRANSVAGINAL ultrasonography - Abstract
This review concentrates on 2 consequences of cesarean deliveries that may occur in a subsequent pregnancy. They are the pathologically adherent placenta and the cesarean scar pregnancy. We explored their clinical and diagnostic as well as therapeutic similarities. We reviewed the literature concerning the occurrence of early placenta accreta and cesarean section scar pregnancy. The review resulted in several conclusions: (1) the diagnosis of placenta accreta and cesarean scar pregnancy is difficult; (2) transvaginal ultrasound seems to be the best diagnostic tool to establish the diagnosis; (3) an early and correct diagnosis may prevent some of their complications; (4) curettage and systemic methotrexate therapy and embolization as single treatments should be avoided if possible; and (5) in the case of cesarean scar pregnancy, local methotrexate- and hysteroscopic-directed procedures had the lowest complication rates. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
30. Placental extracellular vesicles-associated microRNA-519c mediates endotoxin adaptation in pregnancy.
- Author
-
Tiozzo, Caterina, Bustoros, Mark, Lin, Xinhua, Manzano De Mejia, Claudia, Gurzenda, Ellen, Chavez, Martin, Hanna, Iman, Aguiari, Paola, Perin, Laura, and Hanna, Nazeeh
- Subjects
PLACENTA ,SMALL interfering RNA ,ENDOTOXINS ,TUMOR necrosis factors ,EXTRACELLULAR vesicles ,PLACENTA diseases ,CHORIOAMNIONITIS - Abstract
Background: Pregnancy represents a unique challenge for the maternal-fetal immune interface, requiring a balance between immunosuppression, which is essential for the maintenance of a semiallogeneic fetus, and proinflammatory host defense to protect the maternal-fetal interface from invading organisms. Adaptation to repeated inflammatory stimuli (endotoxin tolerance) may be critical in preventing inflammation-induced preterm birth caused by exaggerated maternal inflammatory responses to mild or moderate infections that are common during pregnancy. However, the exact mechanisms contributing to the maintenance of tolerance to repeated infections are not completely understood. MicroRNAs play important roles in pregnancy with several microRNAs implicated in gestational tissue function and in pathologic pregnancy conditions. MicroRNA-519c, a member of the chromosome 19 microRNA cluster, is a human-specific microRNA mainly expressed in the placenta. However, its role in pregnancy is largely unknown.Objective: This study aimed to explore the role of "endotoxin tolerance" failure in the pathogenesis of an exaggerated inflammatory response often seen in inflammation-mediated preterm birth. In this study, we investigated the role of microRNA-519c, a placenta-specific microRNA, as a key regulator of endotoxin tolerance at the maternal-fetal interface.Study Design: Using a placental explant culture system, samples from term and second-trimester placentas were treated with lipopolysaccharide. After 24 hours, the conditioned media were collected for analysis, and the placental explants were re-exposed to repeated doses of lipopolysaccharide for 3 days. The supernatant was analyzed for inflammatory markers, the presence of extracellular vesicles, and microRNAs. To study the possible mechanism of action of the microRNAs, we evaluated the phosphodiesterase 3B pathway involved in tumor necrosis factor alpha production using a microRNA mimic and phosphodiesterase 3B small interfering RNA transfection. Finally, we analyzed human placental samples from different gestational ages and from women affected by inflammation-associated pregnancies.Results: Our data showed that repeated exposure of the human placenta to endotoxin challenges induced a tolerant phenotype characterized by decreased tumor necrosis factor alpha and up-regulated interleukin-10 levels. This reaction was mediated by the placenta-specific microRNA-519c packaged within placental extracellular vesicles. Lipopolysaccharide treatment increased the extracellular vesicles that were positive for the exosome tetraspanin markers, namely CD9, CD63, and CD81, and secreted primarily by trophoblasts. Primary human trophoblast cells transfected with a microRNA-519c mimic decreased phosphodiesterase 3B, whereas a lack of phosphodiesterase 3B, achieved by small interfering RNA transfection, led to decreased tumor necrosis factor alpha production. These data support the hypothesis that the anti-inflammatory action of microRNA-519c was mediated by a down-regulation of the phosphodiesterase 3B pathway, leading to inhibition of tumor necrosis factor alpha production. Furthermore, human placentas from normal and inflammation-associated pregnancies demonstrated that a decreased placental microRNA-519c level was linked to infection-induced inflammatory pathologies during pregnancy.Conclusion: We identified microRNA-519c, a human placenta-specific microRNA, as a novel regulator of immune adaptation associated with infection-induced preterm birth at the maternal-fetal interface. Our study serves as a basis for future experiments to explore the potential use of microRNA-519c as a biomarker for infection-induced preterm birth. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
31. Chronic histiocytic intervillositis: manifestation of placental alloantibody-mediated rejection.
- Author
-
Benachi, Alexandra, Rabant, Marion, Martinovic, Jelena, Bouchghoul, Hanane, Vivanti, Alexandre J., Leon, Juliette, Grunenwald, Anne, Roumenina, Lubka, Celton, Jean-Louis, Bessieres, Bettina, Taupin, Jean-Luc, and Zuber, Julien
- Subjects
RECURRENT miscarriage ,HLA histocompatibility antigens ,PLACENTA ,FETAL growth retardation ,GRAFT rejection ,FETAL death ,RESEARCH ,IMMUNOGLOBULINS ,PRENATAL diagnosis ,PLACENTA diseases ,RESEARCH methodology ,DIFFERENTIAL diagnosis ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,CHORIONIC villi - Abstract
Background: Chronic histiocytic intervillositis (chronic intervillositis) is defined by a diffuse infiltration of monocytes into the intervillous space, which often leads to poor obstetrical outcomes, including recurrent intrauterine growth restriction, miscarriage, and fetal death. The pathogenesis of chronic intervillositis is still poorly defined, and there is an unmet medical need for improved management.Objective: This study aimed to demonstrate the role of anti-human leukocyte antigen alloantibodies in the pathogenesis of chronic intervillositis through the application of criteria used in solid-organ transplantation for the diagnosis of antibody-mediated rejection.Study Design: A multidisciplinary research study based on thorough immunologic and pathologic investigations was carried out for 2 separate couples who experienced recurrent secondary fetal losses following a first normal pregnancy associated with histologic evidence of chronic intervillositis.Results: Very high levels of complement-fixing, fetus-specific antibodies targeting mismatched human leukocyte antigen alleles, harbored by the 2 paternal haplotypes, were identified in both cases. Polymorphic human leukocyte antigens were expressed on the surface of trophoblastic villi of the inflamed placenta but not in healthy placental tissue. The binding of alloantibodies to paternal human leukocyte antigens induced dramatic activation of the complement classical pathway in trophoblastic villi, leading to C4d deposition and formation of the terminal complex C5b-9. All requirements for the diagnosis of antibody-mediated placental rejection were fulfilled according to the criteria used in the Banff classification of allograft pathology. In silico analysis was performed using a human leukocyte antigen epitope viewer to reconstitute the human leukocyte antigen sensitization history. Reactivity against a single mismatched epitope present in the first-born healthy child accounted for a broad sensitization to human leukocyte antigens, including those harbored by the 2 paternal haplotypes. This finding explained the high rates of chronic intervillositis recurrence during subsequent pregnancies.Conclusion: This study provides novel mechanistic insights into the pathogenesis of chronic intervillositis and provides new avenues for individualized counseling and therapeutic options. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
32. Delayed hysterectomy: a laparotomy too far?
- Author
-
Collins, Sally L., Sentilhes, Löic, Chantraine, Frederic, and Jauniaux, Eric
- Subjects
HYSTERECTOMY ,ABDOMINAL surgery ,PLACENTA praevia ,CESAREAN section ,BLOOD circulation ,INFANT care ,ALGORITHMS ,LABOR complications (Obstetrics) ,LAPAROSCOPY ,PLACENTA diseases - Published
- 2020
- Full Text
- View/download PDF
33. 1085: Fetal growth restriction in hypertensive vs. smoking women- pregnancy outcomes, ultrasound findings, and placental pathology.
- Author
-
Tairy, Daniel, Kovo, Michal, Zamir, Astar maloul, gandelsman, Erika, Levy, Michal, Herman, Hadas Ganer, Volpert, Eldar, Barda, Giulia, Bar, Jacob, and Weiner, Eran
- Subjects
FETAL development ,PREGNANCY ,PATHOLOGY ,PLACENTA diseases ,ABORTION ,CIGARETTE smoke - Published
- 2020
- Full Text
- View/download PDF
34. 463: Placental expression of HLA-G,C,E, and F in preterm severe preeclampsia and preterm labor.
- Author
-
Hackmon, Rinat, Bucher, Matthew, caroline Dunk, Zhang, Jiahong, Geraghty, Dan, and Myatt, Leslie
- Subjects
PREMATURE labor ,PREECLAMPSIA ,PLACENTA diseases - Published
- 2020
- Full Text
- View/download PDF
35. 104: The association of pathological nuchal translucency to placental complications in cases of normal microarray analysis.
- Author
-
Krispin, Eyal, Kushnir, Anya, Shemer, Assaf, Rienstein, Shlomit, Michal berekendt, Yinon, Yoav, and Weisz, Boaz
- Subjects
PLACENTA diseases ,FETAL development ,GESTATIONAL age ,FETOSCOPY - Published
- 2020
- Full Text
- View/download PDF
36. MaternaL-fetal conditions necessitating a medical intervention resulting in preterm birth.
- Author
-
Ananth, Cande V. and Vintzileos, Anthony M.
- Subjects
PRENATAL influences ,PREMATURE infants ,PREMATURE labor ,PREECLAMPSIA ,FETAL distress ,PLACENTA diseases ,GESTATIONAL age ,CHILDBIRTH ,PREGNANCY complications ,LABOR (Obstetrics) - Abstract
Objective: The objective of the study was to evaluate the extent to which maternal and fetal conditions necessitate medically indicated preterm birth. Study design: A population-based, retrospective, cohort study of women who delivered a single- ton live birth at 20 weeks or longer in Missouri, 1989 to 1997 was performed (n = 684,711). Maternal-fetal conditions that necessitated iatrogenic preterm birth included preeclampsia, small-for-gestational-age birth, fetal distress, placental abruption, placenta previa, unexplained vaginal bleeding, pregestational and gestational diabetes, renal disease, Rh sensitization, and congenital malformations. We examined the association between each of the aforementioned conditions and risk of medically indicated preterm birth at less than 35 weeks. Medically indicated preterm birth was defined as a labor induction or a prelabor cesarean in the absence of premature rupture of membranes at preterm gestations. Adjusted relative risk with 95% confidence interval for preterm birth was derived from multivariable logistic regression models, and population attributable fractions were calculated. Results: The preterm birth rate (less than 35 weeks) was 4.6% (n = 31,238), with 23.5% (n = 7,347) of such births being medically indicated. Preeclampsia, fetal distress, small-for-gestational- age, and placental abruption were the most common indications for a medical intervention resulting in preterm birth, with at least I of these conditions present in 53.2% of medically indicated preterm births and in 17.7% of term births (relative risk 4.9, 95% confidence interval 4.7, 5.2). Conclusion: Preeclampsia, fetal distress, small-for-gestational-age, and placental abruption, conditions that are associated with ischemic placental disease, are implicated in well over half of all medically indicated preterm births. Although the etiology of preterm birth is heterogeneous, it is reasonable that ischemic placental disease may serve as an important pathway to preterm birth. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
37. Placental inflammation and viral infection are implicated in second trimester pregnancy loss.
- Author
-
Srinivas, Sindhu K., Ma, Yujie, Sammet, Mary D., Chou, Doris, McGrath, Cindy, Parry, Samuel, and Elovitz, Michal A.
- Subjects
PLACENTA diseases ,PREGNANCY complications ,INFLAMMATION ,PREMATURE labor ,DURATION of pregnancy ,PREMATURE infants ,VIRUS diseases ,POLYMERASE chain reaction ,POLYMERIZATION - Abstract
Objective: Second trimester pregnancy loss continues to be a poorly understood adverse obstetric outcome. A case control study was performed to determine if: (1) similar to early spontaneous preterm birth, second trimester loss is associated with histologic chorioamnionitis (HCA); and (2) if HCA is present, which organisms may mediate this placental inflammation. Study design: Cases were patients with a spontaneous second trimester loss. Controls were patients who presented for induction of labor for fetal or maternal indications. Nested polymerase chain reaction (PCR) was performed on placental tissues to detect the presence of viruses and pathogenic and atypical bacteria. Chi-square and Fisher exact test were used to determine if HCA and/or the presence of virus or bacteria were significantly associated with second trimester loss. The associations of interest were adjusted for possible confounders using multivariable logistic regression. Results: HCA was more prevalent in cases (67%) than controls (16%) (P < .001). Seventy-nine percent (66/84) of cases and 44% (7/16) of controls were positive for any virus (P = .01). The rate of bacterial infection was similar in both cases and controls (P = .35). In multivariable logistic regression models, HCA (odds ratio [OR] 14.58, 2.62–81.15) and the presence of any virus (OR 6.62, 1.56–28.07) were independently associated with second trimester loss. Conclusion: These studies demonstrate that spontaneous second trimester loss is strongly associated with HCA and viral infections. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
38. Unequal placental sharing and birth weight discordance in monochorionic diamniotic twins.
- Author
-
Fick, Andrea L., Feldstein, Vickie A., Norton, Mary E., Fyr, Christina Wassel, Caughey, Aaron B., and Machin, Geoffrey A.
- Subjects
BIRTH weight ,TWINS ,PREGNANCY complications ,PLACENTA diseases ,UMBILICAL cord ,GESTATIONAL age ,PRENATAL diagnosis ,MULTIPLE birth ,MULTIPLE pregnancy ,CHI-squared test ,MULTIVARIATE analysis ,LOGISTIC regression analysis - Abstract
Objective: The purpose of this study was to define the association between unequal placental sharing and birth weight discordance in monochorionic/diamniotic twin pregnancies. Study design: The study comprised a prospective cohort of monochorionic/diamniotic twin pregnancies who were delivered in Kaiser Permanente-Northern California, 1997-2003. Dye injection studies of fresh postpartum placentas were performed. Placental sharing, cord insertion combinations, vascular anastomoses, gestational age, and birth weights were recorded. Statistical comparisons of birth weight and gestational age were made with the Student t test. Rates of birth weight discordance were compared with the chi-square test. Multivariate logistic regression models analyzed the relationship between variables of interest. Results: Mean birth weights for larger and smaller twins were 2400 g and 2109 g, respectively. Twenty-two percent of the monochorionic/diamniotic twin pairs had birth weight discordance ≥20%, and 8% of these pairs had twin-twin transfusion syndrome. Monochorionic/diamniotic twin pairs with unequal placental sharing had a 9.8 times greater likelihood of birth weight discordance (95% CI, 5.4–17.9) as compared with those pairs with equal placental sharing. Conclusion: Unequal placental sharing is a significant risk factor for birth weight discordance in monochorionic/diamniotic twins. Antenatal diagnosis of unequal placental sharing would enable improved counseling in the setting of monochorionic/diamniotic twins. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
39. Magnetic resonance imaging for placenta accreta: hope for the future.
- Author
-
Lim, Grace, Lim, Marc, and Horowitz, Jeanne M.
- Subjects
MAGNETIC resonance imaging ,PLACENTA ,PLACENTA praevia ,NUCLEAR magnetic resonance spectroscopy ,LABOR complications (Obstetrics) ,PLACENTA diseases ,ULTRASONIC imaging - Published
- 2019
- Full Text
- View/download PDF
40. Placenta previa-accreta: Risk factors and complications.
- Author
-
Usta, Ihab M., Hobeika, Elie M., Musa, Antoine A. Abu, Gabriel, Gaby E., and Nassar, Anwar H.
- Subjects
PLACENTA diseases ,PLACENTA praevia ,LABOR complications (Obstetrics) ,PREGNANCY complications ,DISEASE risk factors ,CESAREAN section - Abstract
Objective: The purpose of this study was to identify risk factors and complications of placenta previa-accreta (PA). Study design: Patients with placenta previa (n = 347) delivered over 20 years were reviewed, divided into PA (cases, n = 22) and no accreta (controls, n = 325), and compared. Results: Cases were older with a higher incidence of smoking and previous cesarean delivery (CS). Grandmultiparity, recurrent abortions, anterior/central placentae, and low socioeconomic status were similar. PA incidence increased with the number of previous CS: 1.9%, 15.6%, 23.5%, 29.4%, 33.3%, and 50.0% after 0, 1, 2, 3, 4, and 5 previous CS, respectively. Hypertensive disorders (odds ratio [OR] 13.9, 95%CI 2.1-91.2], P = .006), smoking (OR 3.4, 95%CI 1.1-10.2, P = .031) and previous CS (OR 7.9, 95%CI 1.7-37.4, P = .009) were selected by the stepwise logistic regression analysis as predictors of PA. Cases had a longer hospital stay, a higher estimated blood loss, and need for transfusion. Cesarean hysterectomy and hypogastric artery ligation were only performed in PA cases. The 2 groups had a similar delivery gestational age and neonatal outcome. Conclusion: Hypertensive disorders, smoking, and previous cesarean are risk factors for accreta in placenta previa patients. Placenta previa-accreta is associated with higher maternal morbidity, but similar neonatal outcome compared with patients with an isolated placenta previa. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
41. Syncytiotrophoblast intercellular adhesion molecule-1 expression in placental villitis of unknown cause.
- Author
-
Labarrere, Carlos A., Ortiz, Miguel A., Sosa, Marcelo J., Campana, Gonzalo L., Wernicke, Mario, Baldridge, Lee Ann, Terry, Colin, and DiCarlo, Hector L.
- Subjects
CHORIONIC villi ,PLACENTA diseases ,CELL adhesion molecules ,HLA histocompatibility antigens ,EOSIN ,PREGNANCY complications ,DISEASES - Abstract
Objective: The purpose of this study was to determine syncytiotrophoblast intercellular adhesion molecule-1 expression in villitis and in normal chorionic villi from term (37-42 weeks of gestation) placentas with or without villitis. Study design: A cross-sectional study was conducted to determine syncytiotrophoblast intercellular adhesion molecule-1 expression in villitis (n = 16) and in normal villi from placentas with or without villitis (n = 16). Villitis was diagnosed with antibodies to human leukocyte antigen-DR and CD3 and hematoxylin and eosin staining of serial sections; intercellular adhesion molecule I reactivity in syncytiotrophoblast was confirmed with antibodies to intercellular adhesion molecule-1 and cytokeratin. Results: Villitis lesions had higher syncytiotrophoblast intercellular adhesion molecule-1 expression than normal chorionic villi from placentas with (19.9% vs 3.5% villi; P < .001) or without (19.9% vs 0.3 l% villi; P < .001) villitis. Normal villi from placentas with villitis had higher syncytiotrophoblast intercellular adhesion molecule-1 than villi from placentas without villitis (3.5% vs 0.31% villi; P < .001). Conclusion: Placentas with villitis have significantly more syncytiotrophoblast intercellular adhesion molecule-1 expression than placentas without villitis. The finding that normal villi from placentas with villitis have more syncytiotrophoblast intercellular adhesion molecule-1 than normal villi from placentas without villitis suggests that syncytiotrophoblast intercellular adhesion molecule-1 could be the first step in villitis development. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
42. Homocysteine thiolactone induces apoptosis in cultured human trophoblasts: A mechanism for homocysteine-mediated placental dysfunction?
- Author
-
Kamudhamas, Atiwut, Pang, Liyi, Smith, Steven D., Sadovsky, Yoel, and Nelson, D. Michael
- Subjects
HOMOCYSTEINE ,APOPTOSIS ,TROPHOBLAST ,PLACENTA diseases ,PREGNANCY complications ,OBSTETRICS ,GYNECOLOGY - Abstract
Objective: Hyperhomocystinemia is a thrombophilic condition associated with placental dysfunction. We tested the hypothesis that homocysteine-thiolactone, a metabolite of homocysteine, induces apoptosis in cultured trophoblasts. Study design: Cytotrophoblasts from term human placentas were cultured for 72 hours or less in the presence or absence of 50 to 400 μmol/L homocysteine-thiolactone or 400 μmol/L cysteine (control), with or without vitamin C, vitamin E, folate, or N-acetylcysteine. Cell death was assessed by cellular adenosine triphosphate concentration, medium lactate dehydrogenase level, and immunocytochemical staining for the cleavage products of cytokeratin 18 and poly(adenosine diphosphate ribose) polymerase. Changes in expression of p53, Bcl-2, Bax, and Bak were quantified by Western immunoblotting. Results: Homocysteine-thiolactone induced a concentration dependent increase in total cell death and death by apoptosis, compared with control. Vitamin C ameliorated apoptosis in cytotrophoblasts, whereas N-acetylcysteine mitigated cell death in syncytiotrophoblasts. Apoptosis in both phenotypes occurred with increased expression of p53 and Bak, but no change in Bcl-2 or Bax. Conclusion: Homocysteine-thiolactone enhances apoptosis in cultured human trophoblast, and the effect can be limited by antioxidants. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
43. Sonographic detection of placenta accreta in the second and third trimesters of prenancy.
- Author
-
Comstock, Christine H., Love Jr., Joseph J., Bronsteen, Richard A., Lee, Wesley, Vettraino, Ivana M., Huang, Raywin R., and Lorenz, Robert P.
- Subjects
PLACENTA diseases ,PREGNANCY complications ,PLACENTA ,MEDICAL radiography ,ULTRASONIC imaging ,DISEASE risk factors ,PREGNANCY - Abstract
Objective: The purpose of this study was to determine whether ultrasonography can detect placenta accreta reliably in at-risk patients. Study design: All patients with a previous cesarean delivery and an anterior placenta or placenta previa were evaluated prospectively at each visit for sonographic signs of placenta accreta (interruption of the posterior bladder wall-uterine interface, absence of the retroplacental clear zone, and placental lacunae). Results: This evaluation involved 2002 patients over a 12-year period. Of the 14 patients with a confirmed diagnosis of placenta accreta who had ultrasound examinations between 15 and 20 weeks of gestation, the diagnosis was suspected strongly in 86% of the patients (12/14 patients). There were 18 false-positive cases (54.5%; 18/33 patients), most of which were due to a lack of visualization of the echolucent area between the placenta and the myometrium (obliteration of the 'clear space') during the third trimester. The presence of multiple linear irregular vascular spaces within the placenta (placental lacunae) was the diagnostic sign with the highest positive predictive value for placenta accreta. Conclusion: Placenta accreta can be detected as early as 15 to 20 weeks of gestation in most at-risk patients by visualization of irregular vascular spaces within the placenta (placental lacunae). Obliteration of the retroplacental 'clear space' is not a reliable diagnostic sign for placenta accreta. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
44. The frequency and severity of placental findings in women with preeclampsia are gestational age dependent.
- Author
-
Moldenhauer, Julie S., Stanek, Jerzy, Warshak, Carri, Khoury, Jane, and Sibai, Baha
- Subjects
PREECLAMPSIA ,GESTATIONAL age ,PLACENTA diseases - Abstract
Objective: The purpose of this study was to evaluate placental lesions found in women with preeclampsia compared with normotensive control subjects and to determine whether the presence of these lesions are related to gestational age at delivery.Study Design: Placental disease of women with preeclampsia at 24 to 42 weeks of gestation was compared with the placental disease of normotensive gestational age-matched control subjects. The placental lesions that were studied specifically included decidual arteriolopathy, thrombi in the fetal circulation, central infarction, intervillous thrombi, and hypermaturity of villi. Data analysis involved the chi(2) test, the Student t test, and logistic regression; odds ratios and CIs were estimated.Results: Placentas from women with preeclampsia (n=158) and normotensive control subjects (n=156) were evaluated. Among women with preeclampsia, 67% had severe disease. Placental lesions were studied according to gestational age at delivery: <28, 28 to 32, 33 to 36, and >or=37 weeks of gestation. Of the placental lesions that were studied, decidual arteriolopathy (odds ratio, 23.8, 95% CI 10.0-57.0), hypermaturity of villi (odds ratio, 12.4; 95% CI 5.3-29.2), intervillous thrombi (odds ratio, 1.95;95% CI 1.0-3.7), central infarction (odds ratio, 5.9; 95% CI 3.1-11.1), and thrombi in the fetal circulation (odds ratio, 2.8; 95% CI 1.2-6.6) were found to have significantly higher rates in the preeclamptic group. In contrast, the rate of chorioamnionitis was significantly lower in the preeclamptic group (odds ratio, 0.2; 95% CI 0.1-0.4). The rates of abruptio placentae and meconium staining were not different between the two groups. Within the preeclamptic group, the rates of decidual arteriolopathy (P<.0001), central infarction (P=.0001), and hypermaturity of villi (P<.0001) were higher the earlier the gestational age at delivery.Conclusion: Placentas in women with preeclampsia have increased amounts of disease. The rate is increased with lower gestational ages at the time of delivery for women with preeclampsia. [ABSTRACT FROM AUTHOR]- Published
- 2003
- Full Text
- View/download PDF
45. Endothelial cell apoptosis is induced by fetal plasma from pregnancy with umbilical placental vascular disease.
- Author
-
Xin Wang, Shounan Yi, Athayde, Neil, and Trudinger, Brian
- Subjects
APOPTOSIS ,PLACENTA diseases ,PREGNANCY - Abstract
Examines the induction of endothelial cell apoptosis by fetal plasma from pregnancy with umbilical placental vascular disease. Detection of vascular disease in the umbilical placental circulation; Exposure of the isolated and cultured human umbilical vein endothelial cells to fetal plasma; Level of endothelial cell apoptosis.
- Published
- 2002
- Full Text
- View/download PDF
46. Syncytin, a novel human endogenous retroviral gene in human placenta: evidence for its dysregulation in preeclampsia and HELLP syndrome.
- Author
-
Knerr, Ina, Beinder, Ernst, and Rascher, Wolfgang
- Subjects
PREGNANCY complications ,PLACENTA diseases ,GENE expression ,CELL metabolism ,PLACENTA physiology ,RNA metabolism ,MUSCLE proteins ,OXIDOREDUCTASES ,PREECLAMPSIA ,PREGNANCY proteins ,PROTEINS ,REFERENCE values ,RETROVIRUSES ,HELLP syndrome - Abstract
Objective: A novel human endogenous retroviral element, designated as syncytin, has been suggested as a contributor to normal placental architecture, especially in the fusion processes of cytotrophoblasts to syncytiotrophoblasts. We tested the hypothesis of whether the gene expression of syncytin may be altered in cases with placental dysfunction such as preeclampsia or HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome.Study Design: We included 30 women with normal pregnancies, 16 with preeclampsia, and 6 with HELLP syndrome. After delivery, messenger ribonucleic acids (mRNA) of syncytin, glyceraldehyde-3-phosphate dehydrogenase and beta-actin were analyzed in placental villi with use of quantitative real-time polymerase chain reaction.Results: In placental villi, syncytin mRNA/beta-actin mRNA and syncytin mRNA/glyceraldehyde-3-phosphate dehydrogenase mRNA ratios were lower in patients with preeclampsia (P <.05) or HELLP syndrome than in healthy control subjects.Conclusion: A reduced placental expression of syncytin may contribute to altered cell fusion processes in placentogenesis and disturbed placental function in hypertensive disorders of pregnancy. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
47. Regional changes in kynurenic acid, quinolinic acid, and glial fibrillary acidic protein concentrations in the fetal sheep brain after experimentally induced placental insufficiency.
- Author
-
Nicholls, Trish, Lacey, Brendon, Nitsos, Ilias, Smythe, George, and Walker, David W.
- Subjects
QUINOLINIC acid ,GLIAL fibrillary acidic protein ,PLACENTA diseases ,ARTERIAL catheterization ,BRAIN physiology ,SHEEP as laboratory animals - Abstract
Objective: This study was undertaken to examine the effects of chronic embolization of the umbilical circulation during late gestation on regional concentrations of quinolinic acid and kynurenic acid (neuroactive products of tryptophan catabolism) and of the astrocyte-associated glial fibrillary acidic protein in the fetal brain. Study Design: Pregnant ewes bearing fetuses with long-term catheter placement were treated daily with injections of either saline solution (n = 4; control group) or mucopolysaccharide microspheres (n = 5; embolized group) into the umbilical circulation through a femoral artery catheter between 120 and 140 days’ gestation. The fetuses in the embolized group received sufficient microspheres each day to reduce and maintain the femoral arterial P O 2 at ≤12 mm Hg. Autopsies were performed at 140 days’ gestation to obtain the fetal brain for chemical analysis. Results: Umbilical embolization resulted in nonacidemic hypoxia and hypoglycemia at 140 days’ gestation. Quinolinic acid concentrations in the embolized group were significantly increased in the medulla, pons, midbrain, hypothalamus, and hippocampus, whereas kynurenic acid concentrations in the embolized group were reduced in the hippocampus and hypothalamus. There were significant reductions in glial fibrillary acidic protein contents in the occipitoparietal cortex, hippocampus, and pons in the embolized group. Conclusion: Placental compromise during late pregnancy had effects on kynurenine metabolism and astrocyte function in some regions of the fetal sheep brain. We suggest that these changes increase the vulnerability of the brain to asphyxial injury during late gestation and the perinatal period. (Am J Obstet Gynecol 2001;184:203-8.) [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
48. Mathematic modeling to predict abruptio placentae.
- Author
-
Baumann, Peter and Blackwell, Sean C.
- Subjects
PLACENTA diseases ,PREGNANCY complications - Abstract
Studies the correlates of abruptio placentae in the development of a mathematic model for the prediction of the disease. Expression developed for calculating the probability that abruptio placentae will occur; Thirty-one recognized risk factors which proved to be correlates of abruptio placentae; Estimates on the strength of association through binary logistic regression.
- Published
- 2000
- Full Text
- View/download PDF
49. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene as a new risk factor for placental vasculopathy.
- Author
-
van der Molen, Els F., Arends, Guus E., van der Molen, E F, Arends, G E, Nelen, W L, van der Put, N J, Heil, S G, Eskes, T K, and Blom, H J
- Subjects
PLACENTA diseases ,CARDIOVASCULAR diseases in pregnancy ,PREGNANT women - Abstract
Objective: This study was undertaken to investigate whether the cytosine-to-thymine substitution at nucleotide 677 (C677T) in the 5, 10-methylenetetrahydrofolate reductase gene is a risk factor for placental vasculopathy (abruptio placentae or placental infarction with fetal growth restriction).Study Design: This case-control study enrolled 165 women with placental vasculopathy and 139 matched control women with normal pregnancy outcomes. Measurements included fasting total plasma homocysteine concentration, serum and red blood cell folate concentrations, serum vitamin B(12) concentration, whole-blood vitamin B(6) concentration, and analysis of the 5, 10-methylenetetrahydrofolate reductase gene C677T mutation.Results: The median total plasma homocysteine concentration was significantly higher in the study group than in the control group (P <.01; odds ratio >97.5th percentile, 4.66; 95% confidence interval, 1.55-14.0). Homozygous genotype for the mutated 5,10-methylenetetrahydrofolate reductase gene was found in 12% of the study group and 5% of the control group (odds ratio, 2.45; 95% confidence interval, 1.00-6.02).Conclusions: Mild hyperhomocysteinemia was confirmed among women with placental vasculopathy, for which homozygosity for a mutated 5, 10-methylenetetrahydrofolate reductase gene was found to be a new risk factor. The risk of placental vasculopathy probably increases in conditions of low serum folate concentration. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
50. Human immunodeficiency virus infection: In situ polymerase chain reaction localization in human...
- Author
-
Sheikh, Asad U. and Polliotti, Bruno M.
- Subjects
HIV infections ,PLACENTA diseases ,POLYMERASE chain reaction - Abstract
Compares localization of human immunodeficiency virus (HIV) type 1 within human placentas infected in utero with localization within human placental explants infected in vitro. In situ polymerase chain reaction; Preparation of biotin-labeled long-terminal repeat and pol probes by oplymerase chain reaction; Detection of infected cell tissues.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.